NGEN NGEN
Company Profile ↓Company Overview
NGEN (NGEN) is a publicly traded company listed on with a market capitalization of $133.81M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.24.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -31.98% |
| 6 Months: | -60.19% |
| 3 Months: | -55.44% |
| 1 Month: | -16.42% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)40.70 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 71.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | 6.04M | 6.47M | 6.17M | 6.40M | 7.53M |
| Operating Income | - | -6.04M | -6.47M | -6.17M | -6.40M | -7.53M |
| EBITDA | - | -6.02M | -6.46M | -6.16M | -6.39M | -7.53M |
| Interest Expense | - | - | - | - | - | - |
| Pretax Income | - | -3.95M | -9.10M | -4.16M | -26.91M | -1.68M |
| Tax Provision | - | - | - | - | - | - |
| Net Income | - | -3.95M | -9.10M | -4.16M | -26.91M | -1.68M |
| Diluted EPS | - | -0.06 | -0.13 | -0.06 | - | -0.09 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 23.03M | 17.78M | 25.18M | 25.08M |
| Operating Income | - | -23.03M | -17.78M | -25.18M | -25.08M |
| EBITDA | - | -20.09M | -17.63M | -25.09M | -25.02M |
| Interest Expense | 0 | 514.60K | 0 | - | - |
| Pretax Income | - | -20.72M | -22.38M | -24.25M | -44.12M |
| Tax Provision | - | - | - | - | - |
| Net Income | - | -20.72M | -22.38M | -24.25M | -44.12M |
| Diluted EPS | - | -0.39 | -0.38 | -0.36 | -0.61 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 23.88M | 13.24M | 19.49M | 23.21M |
| Current Assets | - | 23.15M | 12.52M | 19.01M | 22.80M |
| Cash & Equivalents | - | 22.45M | 11.66M | 17.27M | 22.07M |
| Inventory | - | - | - | - | - |
| Receivables | 64.00K | 27.03K | 250.21K | - | - |
| Total Liabilities | - | 10.41M | 15.25M | 16.91M | 19.73M |
| Current Liabilities | - | 10.22M | 15.14M | 16.90M | 19.73M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 283.45K | 197.19K | 105.60K | 8.37K |
| Total Equity | - | 13.46M | -2.01M | 2.58M | 3.48M |
| Shares Outstanding | - | 58.78M | 59.61M | 70.33M | 79.65M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -17.78M | -11.30M | -16.84M | -19.50M |
| Investing Cash Flow | - | -21.11K | -138.85K | 58.87K | 100.93K |
| Financing Cash Flow | - | 22.64M | 766.28K | 22.70M | 23.76M |
| Capital Expenditure | -45.09K | -21.11K | -141.40K | - | - |
| Free Cash Flow | - | -17.81M | -11.44M | -16.84M | -19.50M |
| Net Change in Cash | - | 4.84M | -10.67M | 5.91M | 4.37M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | -153.9% | 1,114.0% | -941.2% | -1,268.9% |
| ROCE % | - | -168.6% | 933.9% | -973.9% | -721.3% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NGEN
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTFB1YVFpcVNfekZleGxXdU9QZWdMS19qT09YODJrMmN5WDh4eFBKWVNuUTNodEhBdXd3T0drT2JIczVibVdjeFB6Q0lDMTk5ZC1i?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
Lobbying Update: $50,000 of NERVGEN PHARMA CORP. lobbying was just disclosed | NGEN Stock News - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxNbkY0ekdyUGVGRW5oM2lNd2RuY1h6ZURfZnB1V285YlpQRlFudW9uNkh1NWh3MWRlZGVvWkNWVktNUmVybll1ZmJqTkhxUTZZZ0daYm1zSE5JQmwyc2EtR0NPNXlSc1p4WTR6VjZ6azFERXVlX1QtanQzbGJkbzY0dUxGeS0wcEo3d2tEMX…
NGEN Stock Price and Chart — NASDAQ:NGEN - TradingView
<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTE82Yzlvb29sV3ZUWU5tb0ZtNDVPendKNWViTlloTUVmN1JkNVpIY0U1T1F3TXo5aktRVm54T1ZiOXlSS3BHYW9qc1NDSFZjZlRPaWlSOXQxZ1BFc0ox?oc=5" target="_blank">NGEN Stock Price and Chart — NASDAQ:NGEN</a…
Why Is NervGen Pharma Stock Gaining Tuesday? - Benzinga
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxPNVhUcFItVnEzN01TaGtyblpOa2hXOUFRQlp0cTNBdXZ6WTJHeFN0bDdtRUdwWDRmZEdiSWNfRHNZaXdDcm5KYnBVWFFkOUdHcFRuN3pxUEJUZVlZdHZMNk9tbWNkZjBZTmRjZ1FuMG5HSWtlYlR0XzIxcFp2LUVRUTlVcE9ObWJ4N1Mtd1…
NervGen stock rises as TD Cowen issues new Buy (NGEN:NASDAQ) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiiAFBVV95cUxQR1dINVdoT09jVVdRYUdWNnhrYXRFZ0pPdXNmcjUwN1RvTEZiM1MtYWxzb0xoMGJaVWFhM2E5eDRFMEQxOVBNdDgwS2hBZF9Ic1RUU0NXTks5NkZDV2t5Yk94TTl1OVRRLVNJQXV2X3ZFbnpKMTRHdnJvSU9VVUNzemd0YUVDQ1lC?oc=5"…
When Will NervGen Pharma Corp. (CVE:NGEN) Breakeven? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMif0FVX3lxTE45VnByMjBkZVhzT3VRYzIyZFhnUEV0WWxUOC1qWkpVWThlVzRlMHlTTEpwd1ZITkpUYkJEX20xMUR6VVpuNFU5dVh4Ynpmb0dJbW1XMVVfRmFqWVF0dXdCN24zdGt0UmtuZFhYc0VCS0REaGZzVWRFQm9yWjJBRzQ?oc=5" target="_bla…
NGEN — Frequently Asked Questions
What is the current share price of NGEN?
As of 2026-08-05 17:25 PDT, NGEN trades at $1.68 on NASDAQ/NYSE. Its 52-week range is $1.59 to $5.97.
What is the market capitalisation of NGEN?
NGEN has a market capitalisation of $133.81M on NASDAQ/NYSE.
What is the P/E ratio of NGEN?
NGEN trades at a trailing price-to-earnings (P/E) ratio of -2.75. Its price-to-book (P/B) ratio is 38.44.
Is NGEN a good stock to buy?
This page provides a data-driven analysis of NGEN, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.